167902-99-0

Basic information

• Product Name: 2,4-dioxo-2,4-dihydro-1H-benzo[d][1,3]oxazine-8-carboxylic acid
• Synonyms: 2,4-dioxo-2,4-dihydro-1H-benzo[d][1,3]oxazine-8-carboxylic acid;3-Carboxyisatoic acid anhydride, 8-Carboxy-1,4-dihydro-2,4-dioxo-2H-3,1-benzoxazine
• CAS NO: 167902-99-0
• Molecular Formula: C₉H₅NO₅
• Molecular Weight: 207.1397
• Mol File: 167902-99-0.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2,4-dioxo-2,4-dihydro-1H-benzo[d][1,3]oxazine-8-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-dioxo-2,4-dihydro-1H-benzo[d][1,3]oxazine-8-carboxylic acid(167902-99-0)
• EPA Substance Registry System: 2,4-dioxo-2,4-dihydro-1H-benzo[d][1,3]oxazine-8-carboxylic acid(167902-99-0)

Safety Data

• Hazardous Substances Data: 167902-99-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,4-dioxo-2,4-dihydro-1H-benzo[d][1,3]oxazine-8-carboxylic acid is used as a potential anti-cancer agent for its potential to exhibit biological activities that could be harnessed in the development of new cancer treatments. Its intricate structure and potential pharmacological effects make it a promising candidate for further research and potential drug development.
Used in Medicinal Chemistry Research:
2,4-dioxo-2,4-dihydro-1H-benzo[d][1,3]oxazine-8-carboxylic acid is used as a subject of study for its potential to contribute to the understanding of molecular interactions and mechanisms of action in the context of disease treatment, particularly in the area of cancer therapeutics. Its unique properties may offer insights into new approaches for drug design and synthesis.

Upstream product

• 25128-35-2 isatin-7-carboxylic acid 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 39622-79-2 2-aminoisophthalic acid 

Downstream Products

• 167903-01-7 2-amino-3-(N-ethylcarbamoyl)benzoic acid 
• 46278-39-1 2-amino-3-(N-methylcarbamoyl)benzoic acid 

Relevant articles and documents

Acid-Catalyzed Synthesis of Isatoic Anhydride-8-Secondary Amides Enables IASA Transformations for Medicinal Chemistry

Quinazolin-dione-N-3-alklyl derivatives are the core scaffolds for several categories of bioactive small molecules, but current synthetic methods are costly, involve environmental hazards, and are not uniformly scalable. Here, we report an inexpensive, flexible, and scalable method for the one-pot synthesis of substituted quinazolin-dione-N-3-alkyls (isomers of isatoic-8-secondary amides (IASAs)) from isatin that take advantage of in situ capture of imidic acid under acidic conditions. We further show that this method can be used for the synthesis of a wide variety of derivatives with medicinal uses.

MODIFIED PROTEINS AND PROTEIN DEGRADERS

Provided herein are compounds, pharmaceutical compositions, and methods for binding or degrading target proteins. Further provided herein are compounds having a DNA damage-binding protein 1 (DDB1) binding moiety. Some such embodiments include a linker. Some such embodiments include a target protein binding moiety. Further provided herein are ligand-DDB1 complexes. Further provided herein are in vivo modified DDB1 proteins.

Antitumor imidazotetrazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide

A series of new imidazo[5,1-d]-1,2,3,5-tetrazinones with additional hydrogen-bonding or ionic substituents at the 8-carboxamide position of the antitumor drugs temozolomide (1) and mitozolomide (2) has been prepared. None of these compounds were significantly more cytotoxic in vitro against the mouse TLX5 lymphoma than the lead structures. Molecular modeling techniques have been used to design benzo- and pyrazolo[4,3-d]-1,2,3-triazinones bearing carboxamide groups in appropriate positions which are isosteric with temozolomide and mitozolomide but which cannot ring open to alkylating species. As predicted, these compounds have no inhibitory properties against human GM892A or Raji cell lines in vitro. Temozolomide and the spermidine- temozolomide conjugate 28 preferentially methylate guanines within guanine- rich sequences in DNA, but no experimental evidence has been found to support the hypothesis that such regions are involved in catalyzing the ring opening of the imidazotetrazinone prodrugs to their active forms.